Regeneron's Push Into Obesity, Q4 2023 Earnings Review

ruizluquepazRegeneron (NASDAQ:REGN) has made significant progress since I initiated coverage in the summer of 2022 which was the time of the acquisition of Libtayo rights from partner Sanofi (SNY). I argued at the time that this was a great deal for Regeneron and shortly thereafter, that the company should return to growth after the revenue decline driven by the disappearance of COVID-19 revenues, and that the EV/revenue multiple should start to expand from below 5 to the 7-8 range and up to 10 during e ...